Literature DB >> 15888940

Antifungal combinations.

Roxana G Vitale1, Javier Afeltra, Eric Dannaoui.   

Abstract

The increase in fungal infections and the change in fungal epidemiology is caused by the extensive use of antifungal agents to treat fungal infections that are being diagnosed in severly immunocompromised hosts. In addition, opportunistic fungal infections resistant to antifungal drugs have become increasingly common, and the armamentarium for treatment remains limited. A possible approach to overcoming these problems is to combine antifungal drugs, especially if the mechanisms of action are different. The in vitro test is the first step to evaluate possible antifungal combinations. In this chapter, the three most frequently used metholodologies are described: checkerboard, E-test, and time-kill curves. The description of each technique and intrepretaion of the results are addressed in detail.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888940     DOI: 10.1385/1-59259-943-5:143

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  16 in total

1.  Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.

Authors:  Patrick Schwarz; Guilhem Janbon; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

2.  In Vitro activity of terbinafine combined with caspofungin and azoles against Pythium insidiosum.

Authors:  Ayrton S Cavalheiro; Grazieli Maboni; Maria I de Azevedo; Juliana S Argenta; Daniela I B Pereira; Tatiana B Spader; Sydney H Alves; Janio M Santurio
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

3.  In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp.

Authors:  Virginie Planche; Sebastien Ducroz; Alexandre Alanio; Marie-Elisabeth Bougnoux; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

Review 4.  Review: Global nutrient profiling by Phenotype MicroArrays: a tool complementing genomic and proteomic studies in conidial fungi.

Authors:  Lea Atanasova; Irina S Druzhinina
Journal:  J Zhejiang Univ Sci B       Date:  2010-03       Impact factor: 3.066

5.  Administration of Zinc Chelators Improves Survival of Mice Infected with Aspergillus fumigatus both in Monotherapy and in Combination with Caspofungin.

Authors:  Paris Laskaris; Ahmad Atrouni; José Antonio Calera; Christophe d'Enfert; Hélène Munier-Lehmann; Jean-Marc Cavaillon; Jean-Paul Latgé; Oumaïma Ibrahim-Granet
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  In Vitro Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp.

Authors:  A Raffetin; V Courbin; V Jullien; E Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  Synergistic In Vitro Interaction of Isavuconazole and Isoquercitrin against Candida glabrata.

Authors:  Petra V Schwarz; Ilya Nikolskiy; Eric Dannaoui; Frank Sommer; Gert Bange; Patrick Schwarz
Journal:  J Fungi (Basel)       Date:  2022-05-20

8.  In Vitro Antifungal Combination of Terbinafine with Itraconazole against Isolates of Trichophyton Species.

Authors:  Anne-Laure Bidaud; Patrick Schwarz; Anuradha Chowdhary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2021-10-11       Impact factor: 5.938

9.  Small-molecule suppressors of Candida albicans biofilm formation synergistically enhance the antifungal activity of amphotericin B against clinical Candida isolates.

Authors:  Jianlan You; Lin Du; Jarrod B King; Brian E Hall; Robert H Cichewicz
Journal:  ACS Chem Biol       Date:  2013-02-14       Impact factor: 5.100

10.  Molecular epidemiology and antifungal susceptibility profiles of clinical Cryptococcus neoformans/Cryptococcus gattii species complex.

Authors:  Zainab Bandalizadeh; Tahereh Shokohi; Hamid Badali; Mahdi Abastabar; Farhang Babamahmoudi; Lotfolah Davoodi; Masoud Mardani; Mostafa Javanian; Hamed Cheraghmakani; Ali Asghar Sepidgar; Parisa Badiee; Sadegh Khodavaisy; Setareh Agha Kuchak Afshari; Kazem Ahmadikia; Seyedmojtaba Seyedmousavi
Journal:  J Med Microbiol       Date:  2020-01       Impact factor: 2.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.